ASH 2019 CAR-T cell therapy in myeloma

CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Hematology (ASH) Annual Meeting. Dr Mohamad Mohty, Head of Hematology and and cellular therapy department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarised for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASH.